TIL - NASDAQ

Instil Bio, Inc.

TIL·NASDAQ

$8.10

-0.84%

HealthcareBiotechnology

Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize folate receptor alpha (FOLR1) with indications, including gynecological, non-small cell lung cancer, renal caner, and others. The company was incorporated in 2018 and is headquartered in Dallas, Texas.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$54.94M

EPS-10.7000

P/E Ratio-0.76

Earnings Date08/07/2026

-36.62M

Operating Cash Flow

-34%

3Y-80.0%

5Y+24.0%

10Y+592.0%

25.48M

Investing Cash Flow

-53%

3Y-78.0%

5Y-150.0%

10Y-3452.0%

7.29M

Financing Cash Flow

315%

3Y-90.0%

5Y-98.0%

10Y-51.0%

Instil Bio, Inc. Cash Conversion Engine

TIL · NASDAQ

FCF Components

Net Income-71.37M

Depreciation & Amortization534.00K

Stock-Based Compensation8.69M

Change in Working Capital-560.00K

Others26.09M

Capital Expenditures0.00

Free Cash Flow-36.62M

Cash Flow Quality Analysis

FCF Conversion Rate

51.3%

Weak cash conversion. Significant portion of earnings not converting to cash—review working capital trends and capital intensity.

FCF Growth Trend

+44.3%

Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.

Working Capital Impact

-$560.00K

Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.

Cash Flow Quality Insight

Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.

Instil Bio, Inc. Cash Flow Statement

TIL • NASDAQ

Instil Bio, Inc. Cash Flow Statement	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
OPERATING ACTIVITIES
Net Income	-71.4M	-74.1M	-156.1M	-223.2M	-156.8M	-37.7M	-6.5M
Depreciation & Amortization	534K	3.6M	4.8M	6M	2.8M	256K	20K
Change in Deferred Taxes	0.0	0.0	0.0	0.0	710K	0.0	0.0
Stock-Based Compensation	8.7M	17.3M	18.2M	30.4M	26.2M	1.7M	293K
Other Non-Cash Items	26.1M	10.2M	60.2M	16.2M	636K	4.7M	550K
Change in Working Capital	-560K	-12.6M	-9M	-9.6M	4.4M	1.5M	366K
Cash from Operating Activities	-36.6M	-55.7M	-82M	-180.2M	-122.1M	-29.6M	-5.3M
INVESTING ACTIVITIES
Investments in Property, Plant, and Equipment	-10M	-10M	-20.7M	-84.6M	-57.8M	-50.8M	-760K
Acquisitions, Net	(432K)	(0.0)	(0.0)	(1.2M)	(0.0)	-306K	(0.0)
Purchase of Investments	-100.9M	-135.6M	-301.5M	-666.2M	-1.1B	(0.0)	(0.0)
Sale/Maturity of Investments	135.9M	198.7M	361.7M	865.4M	691M	0.0	0.0
Other Investing Items	0.0	866K	1.6M	-1.2M	0.0	0.0	0.0
Cash from Investing Activities	(25.5M)	(54M)	(41.1M)	(114.5M)	-474.4M	-51.1M	-760K
FINANCING ACTIVITIES
Net Issuance of Common Stock	853K	0.0	0.0	1.5M	339M	0.0	0.0
Net Issuance of Debt	6.6M	2.8M	8.1M	70.3M	0.0	0.0	0.0
Other Financing Items	-172K	-1M	0.0	0.0	1.7M	430K	0.0
Cash from Financing Activities	7.3M	1.8M	8.1M	71.9M	393.2M	313M	14.9M
CASH FLOW SUMMARY
Effect of Foreign Exchange Rates	20K	-94K	-201K	-637K	-304K	559K	0.0
Net Change in Cash	-3.8M	-61K	-33M	5.6M	-203.7M	232.9M	8.9M
Cash at Beginning of Period	10.6M	10.7M	43.7M	38.1M	241.8M	8.9M	0.0
Cash at End of Period	6.8M	10.6M	10.7M	43.7M	38.1M	241.8M	8.9M
Free Cash Flow	-36.6M	-65.7M	-102.7M	-264.8M	-180M	-80.4M	-6.1M

SEC Filings

TIL - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
10-Q 10-Q 2026 Q1 Q1	May 15, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 15, 2026	May 15, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 24, 2026	June 11, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 03, 2026	April 01, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 27, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 27, 2026	March 27, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 06, 2026	January 05, 2026	2026	View Filing
10-Q 10-Q 2025 Q3 Q3	November 13, 2025	September 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 13, 2025	November 13, 2025	2025	View Filing
8-K 8-K 2025 N/A	August 13, 2025	August 13, 2025	2025	View Filing

Showing 1 to 10 of 96 filings

Related Guides

Blog Categories

Continue your TIL research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.